WANG Zhiyi, GAO Lei, HU Shaopu, et al. Discussion on tumor immune microenvironment and the application of traditional Chinese medicine based on the theory of "healthy and evil qi"[J]. Modern Chinese Clinical Medicine, 2023, 30(6): 71-75.
DOI:
WANG Zhiyi, GAO Lei, HU Shaopu, et al. Discussion on tumor immune microenvironment and the application of traditional Chinese medicine based on the theory of "healthy and evil qi"[J]. Modern Chinese Clinical Medicine, 2023, 30(6): 71-75.DOI: 10.3969/j.issn.2095-6606.2023.06.016.
Discussion on tumor immune microenvironment and the application of traditional Chinese medicine based on the theory of "healthy and evil qi"
Tumor immune microenvironment (TIME) plays an important role in the development and treatment outcome of tumors. TIME is always in the dynamic confrontation process of anti-tumor and tumor promotion
has consistency with the theory of "healthy and evil qi" in traditional Chinese medicine. According to the role of various immune cells
cytokines
chemokines in tumor development
they can be classified to the "healthy qi" and "evil qi" . The factors that can enhance the anti-tumor immune function and inhibit the tumor proliferation
growth and metastasis belong to the category of healthy qi
while those that destroy the immune homeostasis
inhibit the anti-tumor immune function or enhance the pro-tumor function are evil qi. The occurrence of tumor is caused by the imbalance of healthy and evil qi and the dominant position of the evil side. The formation of tumor immunosuppressive microenvironment can be regarded as the micro embodiment of the combat between the two sides
in which the evil defeats the healthy. Resolving evil by healthy qi plays an important role in the formation of the tumor immunosuppressive microenvironment. Reinforcing healthy qi is a method to supplement the healthy factors
enhances the activity and infiltration state of immune cells
and improves the body’s anti-tumor immunity. Traditional Chinese medicine can inhibit the polarization of negative immune cells and relieve the state of immune suppression
so as to achieve this purpose. Based on the relationship between the healthy and evil qi in TIME
the advantages of TCM rectifying and correcting can be fully played.
SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .
LV B , WANG Y , MA D , et al . Immunotherapy:reshape the tumor immune microenvironment [J/OL]. Front Immunol , 2022 , 13 : 844142 [ 2022-11-10 ]. https://www.frontiersin.org/articles/10.3389/fimmu.2022.844142/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.844142/full .
GUBIN M M , VESELY M D . Cancer immunoediting in the era of immuno-oncology [J]. Clin Cancer Res , 2022 , 28 ( 18 ): 3917 - 3928 .
DESAI , COXON A T , DUNN G P . Therapeutic applications of the cancer immunoediting hypothesis [J/OL]. Semin Cancer Biol , 2022 , 78 : 63 - 77 [ 2022-11-10 ]. https://www.sciencedirect.com/science/article/abs/pii/S1044579X21000523 https://www.sciencedirect.com/science/article/abs/pii/S1044579X21000523 .
WANG Y , JIA A , BI Y , et al . Targeting myeloid-derived suppressor cells in cancer immunotherapy [J/OL]. Cancers , 2020 , 12 ( 9 ): 2626 [ 2022-11-10 ]. https://www.mdpi.com/2072-6694/12/9/2626 https://www.mdpi.com/2072-6694/12/9/2626 .
PAN Y , YU Y , WANG X , et al . Tumor-associated macrophages in tumor immunity [J/OL]. Front Immunol , 2020 , 11 : 583084 [ 2022-11-10 ]. https://www.frontiersin.org/articles/10.3389/fimmu.2020.583084/full https://www.frontiersin.org/articles/10.3389/fimmu.2020.583084/full .
CHANMEE T , ONTONG P , KONNO K , et al . Tumor-associated macrophages as major players in the tumor microenvironment [J]. Cancers(Basel) , 2014 , 6 ( 3 ): 1670 - 1690 .
VESELY M D , KERSHAW M H , SCHREIBER R D , et al . Natural innate and adaptive immunity to cancer [J/OL]. Annu Rev Immunol , 2011 , 29 : 235 - 271 [ 2022-11-10 ]. https://doi.org/10.1146/annurev-immunol-031210-101324 https://doi.org/10.1146/annurev-immunol-031210-101324 .
CAMPBELL D J . Control of regulatory T cell migration,function,and homeostasis [J]. J Immunol , 2015 , 195 ( 6 ): 2507 - 2513 .
LI C , JIANG P , WEI S , et al . Regulatory T cells in tumor microenvironment:new mechanisms,potential therapeutic strategies and future prospects [J/OL]. Mol Cancer , 2020 , 19 ( 1 ): 116 [ 2022-11-10 ]. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01234-1 https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01234-1 .
CHEN X , CHEN X , GAO J , et al . Astragaloside III enhances anti-tumor response of NK cells by elevating NKG2D and IFN-Γ [J/OL]. Front Pharmacol , 2019 , 10 : 898 [ 2022-11-10 ]. https://www.frontiersin.org/articles/10.3389/fphar.2019.00898/full https://www.frontiersin.org/articles/10.3389/fphar.2019.00898/full .
JIANG X , CAO G , GAO G , et al . Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12 [J]. J Cell Physiol , 2021 , 236 ( 1 ): 193 - 204 .
ZHUANG H , DAI X , ZHANG X , et al . Sophoridine suppresses macrophage-mediated immunosuppression through TLR4/IRF 3 pathway and subsequently upregulates CD8 + T cytotoxic function against gastric cancer [J/OL]. Biomedecine Pharmacother , 2020 , 121 : 109636 [ 2022-11-10 ]. https://www.sciencedirect.com/science/article/pii/S0753332219352588 https://www.sciencedirect.com/science/article/pii/S0753332219352588 .
CHEN D , YANG Y , YANG P . Quxie capsule inhibits colon tumor growth partially through Foxo1-mediated apoptosis and immune modulation [J/OL]. Integr Cancer Ther , 2019 , 18 : 1534735419846377 [ 2022-11-10 ]. https://journals.sagepub.com/doi/10.1177/1534735419846377 https://journals.sagepub.com/doi/10.1177/1534735419846377 .
ZHOU J , LI X , WU X , et al . Exosomes released from tumor-associated macrophages transfer miRNAs that induce a treg/Th17 cell imbalance in epithelial ovarian cancer [J]. Cancer Immunol Res , 2018 , 6 ( 12 ): 1578 - 1592 .